Tenaya Therapeutics (NASDAQ:TNYA) Upgraded by Lifesci Capital to Strong-Buy Rating

Lifesci Capital upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.

A number of other equities research analysts also recently issued reports on TNYA. HC Wainwright reduced their price objective on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. Canaccord Genuity Group reduced their target price on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, Chardan Capital decreased their price target on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.50.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.89 on Thursday. The firm has a 50-day moving average of $0.72 and a 200-day moving average of $1.13. Tenaya Therapeutics has a one year low of $0.36 and a one year high of $2.35. The company has a market cap of $145.40 million, a P/E ratio of -1.14 and a beta of 3.22.

Insider Transactions at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total transaction of $1,966,622.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 8,594,047 shares of company stock worth $5,430,207. Insiders own 48.65% of the company’s stock.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of large investors have recently made changes to their positions in the stock. Scientech Research LLC purchased a new position in shares of Tenaya Therapeutics in the third quarter valued at $27,000. Mirador Capital Partners LP lifted its holdings in Tenaya Therapeutics by 38.2% during the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock worth $38,000 after purchasing an additional 6,500 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in Tenaya Therapeutics in the 3rd quarter worth about $99,000. Persistent Asset Partners Ltd bought a new position in Tenaya Therapeutics in the 3rd quarter worth about $117,000. Finally, Savant Capital LLC purchased a new position in Tenaya Therapeutics during the 2nd quarter valued at about $52,000. 90.54% of the stock is owned by institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.